Two stocks in Healthcare
CVS Health vs Gilead Sciences: profit, growth, debt and price compared
CVS Health is stronger on 5 of 7 figures: profit margin, debt, price for its expected profit, dividend and analysts' view. Gilead Sciences is stronger on 2: sales growth and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| CVS HealthCVS | Gilead SciencesGILD | |
|---|---|---|
| Net margin | Stronger: 2.6% | −12.5% |
| Revenue growth, past year | +5.37% | Stronger: +6.83% |
| Debt to equity | Stronger: 93.3% | 202.5% |
| Forward P/E | Stronger: 9.3× | 16.6× |
| Dividend yield | Stronger: 3.27% | 1.92% |
| Analysts | Stronger: Strong buy · 26 | Buy · 26 |
| From its 200-day average | −7.3% | Stronger: +19.3% |
Share price over the past year
- CVS Health+4.4%
- Gilead Sciences+32.9%
18 Nov 202518 Nov 2026
CVS Health or Gilead Sciences: which is stronger?
- CVS
Which is more profitable?
CVS Health keeps more of each sale as profit: 2.6% against −12.5%.
- GILD
Which is growing its sales faster?
Gilead Sciences is growing its sales faster: +6.83% over the past year, against +5.37%.
- CVS
Which has borrowed less?
CVS Health has borrowed less: its debt is 93.3% of what its shareholders own, against 202.5% for Gilead Sciences.
- CVS
Which costs less for the profit it is expected to make?
CVS Health costs less for the profit it is expected to make: 9.3× its forward earnings, against 16.6×.
- CVS
Which pays more in dividends?
CVS Health pays more back in dividends for what a share costs: 3.27% a year, against 1.92%.
- CVS
Which do analysts rate higher?
Analysts are warmer on CVS Health: Strong buy, against Buy for Gilead Sciences.
- GILD
Which is in the stronger price trend?
Gilead Sciences' price is in the stronger trend: 19.3% above its 200-day average, against 7.3% below.
What each company does
CVSCVS Health
CVS Health Corporation provides health solutions in the United States.
Reports results on 9 February 2027
GILDGilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Reports results on 9 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.